Telaprevir
- Generic Name
- Telaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H53N7O6
- CAS Number
- 402957-28-2
- Unique Ingredient Identifier
- 655M5O3W0U
- Background
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 605
- Registration Number
- NCT01492426
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Atlanta Medical Center, Atlanta, Georgia, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT01482390
- Locations
- 🇺🇸
Carolina'S Center For Liver Disease, Statesville, North Carolina, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
🇺🇸Birmingham Gastro Associates, P.C., Birmingham, Alabama, United States
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 121
- Registration Number
- NCT01467492
- Locations
- 🇺🇸
Georgia, Atlanta, Georgia, United States
🇺🇸Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Washington, DC, Washington, District of Columbia, United States
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 185
- Registration Number
- NCT01467479
- Locations
- 🇩🇪
Munchen, Munchen, Germany
🇺🇸Florida, West Palm Beach, Florida, United States
🇺🇸Illinois, Chicago, Illinois, United States
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 61
- Registration Number
- NCT01467505
- Locations
- 🇺🇸
New York, Rochester, New York, United States
🇺🇸North Carolina, Charlotte, North Carolina, United States
🇺🇸Missouri, St Louis, Missouri, United States
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
- Conditions
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 239
- Registration Number
- NCT01459913
- Locations
- 🇺🇸
Virginia, Fairfax, Virginia, United States
🇺🇸Pennsylvania, Hershey, Pennsylvania, United States
🇮🇱Israel, Jerusalem, Israel
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4442
- Registration Number
- NCT01447446
Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism
- Conditions
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- University of Vermont
- Registration Number
- NCT01415141
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Fletcher Allen Health Care, Burlington, Vermont, United States
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01355289
- Locations
- 🇺🇸
Health Care Consultants, Los Angeles, California, United States
🇺🇸Metropolitan Research, Fairfax, Virginia, United States
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
- Conditions
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 70
- Registration Number
- NCT01332955
- Locations
- 🇫🇷
Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Lyon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.